Coverage dated December 28, 2022 to December 29, 2022

Probe: Alzheimer's drug approval 'rife with irregularities'

Headline from KREM Spokane

The criticism comes as the FDA is expected to decide whether to approve another new Alzheimer’s drug in January.

KREM Spokane's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.

Read the reports

Reports & sources

49 articles, oldest first.

Politico
House Dems raise issues with ‘atypical’ FDA review process for Alzheimer's drug (opens Politico)
Published Dec 28, 2022
Politico's feed description
The panels began investigating Aduhelm’s approval and pricing in June 2021, just weeks after it won the FDA’s backing despite questions about the drug’s clinical benefit to patients.
New York Times
Congressional Inquiry into Alzheimer’s Drug Faults Its Maker and F.D.A. (opens New York Times)
Published Dec 28, 2022
New York Times's feed description
The report said the F.D.A.’s approval process for Aduhelm was “rife with irregularities” and criticized Biogen for setting an “unjustifiably high price.”
France 24
US congressional report slams FDA approval of Alzheimer's drug (opens France 24)
Published Dec 28, 2022
France 24's feed description
The US Food and Drug Administration's approval process for a controversial drug used to treat Alzheimer's was "rife with irregularities," a congressional report said Thursday.
The Guardian
FDA under fire over approval of Alzheimer’s drug Aduhelm (opens The Guardian)
Published Dec 28, 2022
The Guardian's feed description
House of Representatives report details ‘corporate greed’ and ‘atypical review process’ preceding agency’s approval of Biogen’s drug
ABC 12 Flint
Congress says FDA approval of Alzheimer's drug was 'rife with irregularities' (opens ABC 12 Flint)
Published Dec 28, 2022
ABC 12 Flint's feed description
A congressional investigation found that the US Food and Drug Administration's "atypical collaboration" to approve a high-priced Alzheimer's drug was "rife with irregularities."
STAT
FDA, Biogen, and an Alzheimer's drug approval: 8 key takeaways from congressional investigation (opens STAT)
Published Dec 28, 2022
STAT's feed description
Here are eight key takeaways from the congressional investigation of the FDA's approval of the Biogen Alzheimer's drug Aduhelm.
Wyoming Tribune Eagle
Congressional Report Slams FDA, Drugmaker Over Approval of Alzheimer's Drug Aduhelm (opens Wyoming Tribune Eagle)
Published Dec 28, 2022
Wyoming Tribune Eagle's feed description
THURSDAY, Dec. 29, 2022 (HealthDay News) -- The U.S. Food and Drug Administration's approval process for the controversial Alzheimer's drug Aduhelm was "rife with irregularities," despite lingering doubts about the
Washington Examiner
House Dems fault FDA's 'atypical' review process for Biogen's Alzheimer's drug (opens Washington Examiner)
Published Dec 28, 2022
Washington Examiner's feed description
The Food and Drug Administration's approval process for Biogen's controversial Alzheimer’s drug was "rife with irregularities," a report from House Democrats concluded.
Boston
Congressional inquiry into Alzheimer’s drug faults Biogen and FDA (opens Boston)
Published Dec 28, 2022
Boston's feed description
The report said the FDA’s approval process for Aduhelm was “rife with irregularities” and criticized Biogen for setting an “unjustifiably high price.”
KREM Spokane
Probe: Alzheimer's drug approval 'rife with irregularities' (opens KREM Spokane)
Published Dec 29, 2022
KREM Spokane's feed description
The criticism comes as the FDA is expected to decide whether to approve another new Alzheimer’s drug in January.
The Daily Caller
Report Finds FDA Colluded With Alzheimer’s Drug Maker During Approval Process (opens The Daily Caller)
Published Dec 29, 2022
The Daily Caller's feed description
A report by multiple House Committees found the Food and Drug Administration (FDA) inappropriately colluded with drug company Biogen.
FOX Business
FDA approval of Alzheimer's drug Aduhelm 'rife with irregularities,' House report says (opens FOX Business)
Published Dec 29, 2022
FOX Business's feed description
A report by two House committees found that the Food and Drug Administration's controversial approval of the Alzheimer's drug Aduhelm was "rife with irregularities."
Los Angeles Times
Alzheimer's drug approval by FDA 'rife with irregularities,' probe finds (opens Los Angeles Times)
Published Dec 29, 2022
Los Angeles Times's feed description
The Food and Drug Administration's contentious approval of a questionable Alzheimer's drug is taking another hit.
Local News 8
House investigation says FDA approval process of Alzheimer's drug was 'rife with irregularities' (opens Local News 8)
Published Dec 29, 2022
Local News 8's feed description
By Jen Christensen, CNN A congressional investigation found that the US Food and Drug Administration’s “atypical collaboration” to approve a high-priced Alzheimer’s drug was “rife with irregularities.” The report, released Thursday, was the result of an 18-month investigation by two House committees…
FOX 5 New York
Alzheimer’s drug approval ‘rife with irregularities,’ investigation finds (opens FOX 5 New York)
Published Dec 29, 2022
FOX 5 New York's feed description
The FDA overruled its advisers in approving the drug, Aduhelm, despite a lack of proof that it met its promise of slowing patients' decline. A high cost and that lack of proof led Medicare to limit the use of the drug.
St. Louis Post-Dispatch
Congressional Report Slams FDA, Drugmaker Over Approval of Alzheimer Drug Aduhelm (opens St. Louis Post-Dispatch)
Published Dec 29, 2022
St. Louis Post-Dispatch's feed description
THURSDAY, Dec. 29, 2022 (HealthDay News) -- The U.S. Food and Drug Administration approval process for the controversial Alzheimer drug Aduhelm was "rife with irregularities," despite lingering doubts about the

Identical headlines usually mean shared wire copy. They are counted as separate articles but are not independent confirmation.